体内研究 (In Vivo) |
Anrikefon (acetate) (0.01-30 mg/kg; i.v.; single dose) 在醋酸诱导的扭体模型中可产生强效、剂量依赖性的、由 KOR 介导的镇痛作用,给药后 15 分钟的 ED50 为 0.09 mg/kg,给药后 24 小时的 ED50 为 1.48 mg/kg,最小有效剂量 (MED) 为 0.03 mg/kg。 Anrikefon (acetate) (0.1-10 mg/kg; i.v.; single dose) 在足底切口模型中产生剂量依赖性的抗异常痛觉作用,给药后 15 分钟的最低有效剂量 (MED) 为 1 mg/kg,在 3 mg/kg 和 10 mg/kg 剂量下,给药后 24 小时仍能维持疗效。 Anrikefon (acetate) (0.1-3 mg/kg;静脉注射;单次给药) 在 CCI 神经病理性疼痛模型中产生剂量依赖性、长效的抗异常痛觉作用,其 MED 为 0.3 mg/kg,且在 1 mg/kg 和 3 mg/kg 剂量下,给药后 24 小时仍能维持疗效。 Anrikefon (acetate) (0.01-3 mg/kg; i.v.; single dose) 在 compound 48/80 诱导的搔抓模型中可产生强效、剂量依赖性的止痒作用,其 ED50 为 0.09 mg/kg,MED 为 0.03 mg/kg。 Anrikefon (acetate) (3.75-30 mg/kg; i.v.; single dose) 在热板模型中表现出较弱的中枢镇痛作用,其 ED50 为 10.49 mg/kg,MED 为 7.5 mg/kg。 Anrikefon (acetate) (0.4-2 mg/kg; i.v.; single dose) 仅在 2 mg/kg 剂量下对健康大鼠产生镇静作用,0.4 mg/kg 剂量下无显著作用。 Anrikefon (acetate) (0.4-2 mg/kg; i.v.; single dose) 在剂量高达 2 mg/kg 时,不会影响健康小鼠的呼吸频率。 Anrikefon (acetate) (0.5-5 mg/kg per injection; i.v.; twice daily; male: 4 weeks prior to mating through mating until day before necropsy, female: 2 weeks prior to mating through mating until gestation day 7) 在最高达 10 mg/kg/day 的剂量下,对雄性大鼠的生育力或早期胚胎发育无具有毒理学意义的影响,但在所有受试剂量下会延长雌性大鼠的动情周期时长并提高周期紊乱率,其雌性生育力毒性的未观察到有害作用水平 (NOAEL) 低于 1 mg/kg/day。 Anrikefon (acetate) (0.1-2 mg/kg per injection; i.v.; twice daily; gestation day 6 through gestation day 17) 对大鼠的胚胎-胎仔发育而言,NOAEL 为 1 mg/kg/day;仅在 4 mg/kg/day 剂量下观察到胎仔胸椎椎体中心骨化不全的发生率略有升高。 Anrikefon (acetate) (0.3-2 µg/kg/day; i.v.; daily; gestation day 7 through gestation day 19) 对家兔胚胎-胎仔发育的无可见有害作用水平 (NOAEL) 为 2 µg/kg/天,在所有测试剂量下均未观察到对母体或胎仔的不良影响。 Anrikefon (acetate) (0.1-2 mg/kg per injection; i.v.; twice daily; gestation day 6 through postnatal day 21) 对大鼠的产前及产后发育的 NOAEL 为 4 mg/kg/天,在所有受试剂量下均未观察到对母鼠或 F1 代后代的不良影响。
| Animal Model: |
ICR (half male and half female, 8-10 weeks old, 18-22 g) |
| Dosage: |
0.01-30 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Induced a 27.46% inhibition of writhing at 0.03 mg/kg (p=0.023 vs. vehicle). Produced dose-dependent inhibitory effects at 0.1, 1, 3, 10 mg/kg at 15 minutes post-dosing (p<0.001 vs. vehicle), with an ED50 of 0.09 mg/kg (95% CI: 0.06-0.12 mg/kg). Reversed antinociceptive effects of 0.3 and 1 mg/kg completely by nor-binaltorphimine. Induced a 32.75% inhibition of writhing at 0.3 mg/kg at 24 hours post-dosing (p=0.02 vs. vehicle). Produced inhibitory rates of 49.67%, 55.60%, 68.12%, and 75.16% at 1, 3, 10, 30 mg/kg respectively at 24 hours post-dosing (p<0.001 vs. vehicle), with an ED50 of 1.48 mg/kg (95% CI: 0.62-2.45 mg/kg). Achieved a minimum effective dose (MED) of 0.03 mg/kg. |
| Animal Model: |
Sprague Dawley (SD) (male, 8-10 weeks old, 160-180 g) |
| Dosage: |
0.1-10 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Induced a 10.5-fold increase in 50% PWT at 1 mg/kg at 15 minutes post-dosing (7.51 g vs. 0.72 g in vehicle group, p=0.001 vs. vehicle). Produced maximum antiallodynic activity at 10 mg/kg at 15 minutes post-dosing, with dose-dependent effects observed across 0.1-10 mg/kg (p<0.001 vs. vehicle). Achieved a MED of 1 mg/kg at 15 minutes post-dosing. Maintained statistically significant increases in 50% PWT at 3 mg/kg (p=0.01 vs. vehicle) and 10 mg/kg (p<0.001 vs. vehicle) at 24 hours post-dosing. |
| Animal Model: |
Sprague Dawley (SD) (male, 8-10 weeks old, 160-180 g) |
| Dosage: |
0.1-3 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Induced a 5.15-fold increase in 50% PWT at 0.3 mg/kg at 15 minutes post-dosing (6.62 g vs. 1.29 g in vehicle group). Produced peak 50% PWT at 2 hours post-dosing at 1 and 3 mg/kg, with statistically significant increases maintained through 24 hours post-dosing. Induced a statistically significant increase in AUC at 0.3 mg/kg (p<0.001 vs. vehicle), while 0.1 mg/kg showed no significant effect at any time point. Achieved a MED of 0.3 mg/kg. |
| Animal Model: |
ICR (male, 8-10 weeks old, 18-22 g) |
| Dosage: |
0.01-3 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Induced a 34.89% inhibition of scratching at 0.03 mg/kg (p=0.015 vs. vehicle). Produced dose-dependent inhibitory effects at 0.1, 0.3, 1, 3 mg/kg (p<0.001 vs. vehicle), with 1 mg/kg inducing a 99.78% inhibition (peak efficacy). Achieved an ED50 of 0.09 mg/kg (95% CI: 0.04-0.16 mg/kg), and a MED of 0.03 mg/kg. |
| Animal Model: |
C57BL/6J (female, 8-10 weeks old, 18-22 g) |
| Dosage: |
3.75-30 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Did not produce significant antinociceptive effects at 3.75 mg/kg (p=0.12 vs. vehicle). Induced a 29.60% MPE at 7.5 mg/kg (p=0.007 vs. vehicle). Achieved an ED50 of 10.49 mg/kg (95% CI: 7.58-15.37 mg/kg), and a MED of 7.5 mg/kg. |
| Animal Model: |
Sprague Dawley (SD) (half male and half female, 8-10 weeks old, 160-180 g) |
| Dosage: |
0.4-2 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Did not significantly affect locomotor activity at 0.4 mg/kg (p=0.16 vs. vehicle). Induced a significant sedative effect at 2 mg/kg (p=0.005 vs. vehicle). |
| Animal Model: |
ICR (half male and half female, 8-10 weeks old, 18-22 g) |
| Dosage: |
0.4-2 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Did not produce significant changes in respiratory rate at 0.4 or 2 mg/kg at any time point post-dosing (p>0.05 vs. vehicle). |
| Animal Model: |
Sprague-Dawley (8-11 weeks, male and female) |
| Dosage: |
1 mg/kg/day; 3 mg/kg/day; 10 mg/kg/day |
| Administration: |
i.v.; twice daily at 6-hour intervals; male: 4 weeks prior to mating through mating until day before necropsy, female: 2 weeks prior to mating through mating until gestation day 7 |
| Result: |
Increased sperm count by 1.19-fold and 1.21-fold vs. vehicle in male rats at 1 and 10 mg/kg/day, within historical control ranges.\nIncreased sperm density by 1.20-fold and 1.23-fold vs. vehicle in male rats at 1 and 10 mg/kg/day, within historical control ranges.\nCaused no changes to sperm motility or morphology in male rats at all doses.\nInduced transient mild body weight decreases in male rats during 4th to 11th day (1, 3 mg/kg/day) or 4th to 15th day (10 mg/kg/day) of dosing.\nIncreased estrous cycle length by 1.10-fold, 1.13-fold, 1.15-fold vs. vehicle in female rats at all doses.\nIncreased estrous cycle disorder rate to 65.4%, 61.5%, 57.7% vs. 23.1% vehicle in female rats at all doses.\nInduced transient mild body weight decreases only on 4th day of dosing in female rats at 1, 3 mg/kg/day.\nIncreased precoital interval in female rats at 10 mg/kg/day.\nDecreased non-gravid uterus weight in female rats at 1 mg/kg/day.\nCaused no treatment-related changes in fertility index, conception index, copulation index, ovarian/uterine contents, or most organ weights. |
| Animal Model: |
Sprague-Dawley (pregnant female) |
| Dosage: |
0.2 mg/kg/day; 1 mg/kg/day; 4 mg/kg/day |
| Administration: |
i.v.; twice daily at 6-hour intervals; gestation day 6 through gestation day 17 |
| Result: |
Induced transient, mild decreases in body weight (3.56%-6.33%) from gestation day 8 to gestation day 10 in maternal rats at 1 and 4 mg/kg/day.\nCaused decreased food consumption from gestation day 6 to gestation day 7 in all dose groups.\nCaused no treatment-related changes in maternal reproductive parameters or organ weights.\nIncreased incidence of incomplete ossification of the thoracic vertebral centrum by 3.5% in fetuses at 4 mg/kg/day.\nCaused no changes to fetal weight, sex ratio, or malformation rates at any dose. |
| Animal Model: |
New Zealand white (5-6 months, pregnant female) |
| Dosage: |
0.3 µg/kg/day; 1 µg/kg/day; 2 µg/kg/day |
| Administration: |
i.v.; daily; gestation day 7 through gestation day 19 |
| Result: |
Caused no treatment-related changes in maternal body weight, food consumption, reproductive parameters, or organ weights at any dose.\nCaused no changes to fetal weight, malformation rates, or visceral development at any dose.\nDecreased male fetal ratio to 32% vs. 41% in controls in fetuses at 2 µg/kg/day, within historical control ranges (18.3%-60.5%) and deemed non-toxicologically significant.\nResulted in plasma concentration ratios between maternal rabbits and fetuses of 109.0 (1 µg/kg/day) and 163.2 (2 µg/kg/day), confirming small amount crosses placental barrier. |
| Animal Model: |
Sprague-Dawley (pregnant female; offspring F1 generation) |
| Dosage: |
0.2 mg/kg/day; 1 mg/kg/day; 4 mg/kg/day |
| Administration: |
i.v.; twice daily at 6-hour intervals; gestation day 6 through postnatal day 21 |
| Result: |
Induced transient, mild decreases in body weight (4.04%-6.56%) from gestation day 8 to gestation day 17 in maternal rats at 1 and 4 mg/kg/day.\nCaused 4.66% decrease in body weight on postnatal day 0 in maternal rats at 1 mg/kg/day.\nIncreased resorptions in maternal rats at 1 mg/kg/day, deemed non-toxicologically significant.\nCaused no treatment-related changes in litter parameters, F1 pup pre-weaning body weight, reflexes, or locomotor activity.\nInduced slight, normal-range body weight increases (3.07%-4.35%) on postnatal day 63-70 in post-weaning F1 females at 1 and 4 mg/kg/day.\nCaused sporadic changes in F1 pup Morris water maze test performance (increased swimming speed in 4 mg/kg/day males on training day 9; increased swimming time in 0.2 and 4 mg/kg/day females on training day 4), deemed non-toxicologically significant.\nAdvanced vaginal opening by 1.54%-1.85% vs. vehicle in F1 females at all doses, deemed non-toxicologically significant.\nCaused no treatment-related changes in F1 pup sexual maturation timing (preputial separation) or reproductive capacity. |
|